TABLE 1.
TM5614 phase II trial patient characteristics
| Number of patients | 33 |
|---|---|
| Median age, years (min‐max) | 59 (23–79) |
| Chronic CML phase (%) | 100 |
| Sex ratio (M/F) | 19/14 |
| Median height, cm (min‐max) | 165.0 (147.5–184.3) |
| Median body weight, kg (min‐max) | 59.7 (47.3–87.0) |
| ECOG Performance status (0/1/2/3‐) | 32/0/1/0 |
| Sokal score risk (Low/Intermediate/High/NA) | 16/5/0/12 |
| Median time since diagnosis, months (range) | 58 (12–260) |
| <36 months | 7 |
| 36 months – <60 months | 10 |
| 60 months – <120 months | 8 |
| 120 months | 8 |
| prior IFN‐α treatment (number) | 1 |
|
prior TKI treatment (IM/DAS/NIL/BOS) [IM/2GTKI] |
7/7/13/6 7/26 |
|
Median BCR‐ABL IS value, % (range) [MMR (≥0.01)/MR4 (<0.01)] |
0.0113 (0.0036–0.0748) 17/16 |
Abbreviations: 2G, second‐generation; BOS, bosutinib; DAS, dasatinib; ECOG, Eastern cooperative oncology group; IFN‐α, interferon‐α; IM, imatinib; NIL, nilotinib; TKI, tyrosine kinase inhibitor.